Pfizer’s chief strategist Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Andrew Baum, a former Citi analyst, has left his role as Pfizer's executive vice president and chief strategy and innovation ...

The healthcare giant has been investing heavily in its future growth.

April 20 (Reuters) - Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will ...

U.S. Food and Drug Administration "enforcement in the social media space has historically been somewhat limited, but recent ...

The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

Before deciding to walk away from the building, Pfizer tried to list nearly half of the 164,000-square-foot campus for ...

In an Untitled Letter, regulators said Facebook promotions for Pfizer’s lymphoma therapy overstated its approved use and ...

Global drug maker Pfizer (PFE) and biotech firm Amgen (AMGN), each valued at over HK$1T ($153B), are among 22 strategic ...

A $500,000 retirement portfolio spread across five income-focused stocks can generate a blended yield of roughly 7.4%, ...